Factors Indicating Need for Dose Escalation Increase doses when minimal subjective improvements after 3-4 weeks at current dose, IGF-1 levels show minimal or no meaningful increase from baseline after an adequate trial period (e.g., 812 weeks), good tolerance without significant side effects suggesting room for higher dosing, and treatment goals require more aggressive approach than current dose provides
While clinical trial data for tirzepatide is excellent, some people prefer the longer track record
GLP-1 medicines belong in that same transformative experience category
However, in non-diabetic obese individuals, its predominant action is appetite suppression and weight reduction
Per l'elenco completo e aggiornato degli ingredienti fare riferimento alla confezione
Use reliable contraception unless actively trying to conceive under medical supervision